LILRB2 and neoplasm: A study by Rouas-Freiss et al. [60] demonstrated the heterogeneity in HLA-G, ILT2 and ILT4 expression in tumor cells and in tumor-infiltrating CD4+ILT2+ and CD8+ILT2+ T cells within renal tumor areas.